United States: Crafting Method Of Treatment Claims To Avoid Multiple Actors

Originally appeared in Law360 on September 17, 2015.

In Limelight Networks Inc. v. Akamai Technologies Inc., the U.S. Supreme Court reversed an en banc decision of the Federal Circuit, which had held that a party may be liable for inducing infringement under 35 U.S.C. § 271(b) if it carries out some steps of a patented method claim and encourages others to carry out the remaining steps of the patented method. 134 S. Ct. 2111, 2116-18 (2014). Under the Federal Circuit's standard, a party could be liable for inducing infringement, even in the absence of a direct infringer practicing the entire patented method. The Supreme Court rejected the Federal Circuit's view, adhering instead to the principle that liability for inducement may arise only where direct infringement occurs. Id. at 2118. The Supreme Court, however, invited the Federal Circuit to revisit its precedent (Muniauction Inc. v. Thomson Corp., 532 F.3d 1318 (2008)), which held that liability for direct infringement under Section 271(a) requires performance of all steps of a method patent to be attributable to a single entity. Limelight, 134 S. Ct. at 2120.

On remand from the Supreme Court, in Akamai Technologies Inc. v. Limelight Networks Inc., the Federal Circuit, sitting en banc, ruled that "[d]irect infringement under § 271(a) occurs where all steps of a claimed method are performed by or attributable to a single entity." 2015 WL 4760450 (Aug. 13, 2015), at *1. When there are multiple actors involved in practicing the steps, the court stated that "a court must determine whether the acts of one are attributable to the other such that a single entity is responsible for the infringement." Id. The court set forth two sets of circumstances where an entity will be responsible for other's performance of method steps: "(1) where that entity directs or controls others' performance, and (2) where the actors form a joint enterprise." Id.

The Supreme Court's Limelight decision together with the Federal Circuit's en banc decision on remand could pose challenges to the enforcement of certain method of treatment patents that may require more than one actor to perform all of the claimed steps. For example, patents involving personalized medicine — where a diagnostic test is often employed for selecting appropriate and optimal therapies based on a patient's genetic information or other molecular or cellular analysis — may claim steps of testing patients with a diagnostic test to identify those having a particular genetic trait and then administering the drug to only those patients. But the actor conducting the diagnostic test may be different from the actor administering the medicine and, depending on circumstances, the acts may not be attributable to, or controlled by, a single entity. If no single entity is responsible for all of the claimed steps there would be no direct infringement. And if there is no underlying direct infringement there would be no inducement.

When drafting claims to cover methods of treatment, it is therefore crucial to ensure that one has claims that do not require multiple actors. Let us assume there is a drug A used to treat prostate cancer for patients with a specific genetic mutation B as identified by a diagnostic test. Here are examples of three claims that can be crafted to avoid multiple actors:

1. A method for treatment of mutation B-positive prostate cancer comprising a step of administering to a human in need thereof an effective amount of drug A.

2. A method for treatment of mutation B-positive prostate cancer comprising a step of administering to a patient who has been identified as having mutation B-positive prostate cancer an effective amount of drug A.

3. A method for treatment of mutation B-positive prostate cancer comprising the steps of selecting a patient who has mutation B-positive prostate cancer, and administering to said selected patient an effective amount of drug A.

In claims 1 and 2, the treatment step consists of administering the drug A to patients who already have been identified as having mutation B-positive prostate cancer. No separate step of testing the patients for mutation B is recited. In claim 3, the "selecting" and the "administering" steps are likely conducted by the same entity, i.e., the doctor who selects the patient who has already been identified as having mutation B-positive prostate cancer and then administers the drug to the patient. Thus, multiple actors are not involved in performing the recited steps.

An accused infringer may argue that in the illustrative claims above, there is an implicit step of testing for patients having mutation B, which is performed by a different actor. To counter this argument one should also have claims that explicitly require an initial testing step to determine whether a patient has mutation B. By doing so, one can invoke the doctrine of claim differentiation to help to construe the claims that do not have an explicit testing step as excluding such a step. The doctrine of claim differentiation creates a presumption that each claim of a patent has different scope. When "a patent claim 'does not contain a certain limitation and another claim does, that limitation cannot be read into the former claim in determining either validity or infringement.'" See SunRace Roots Enterprise Co. v. SRAM Corp., 336 F. 3d 1298, 1302-03 (Fed. Cir. 2003).

Here are examples of claims that can be added to invoke the doctrine of claim differentiation:

4. The method of claim 1 further comprising a step of testing a human to determine whether said human has mutation B-positive prostate cancer prior to said administering step.

5. The method of claim 2 further comprising a step of testing patients to identify a patient having mutation B-positive prostate cancer.

6. The method of claim 3 further comprising a step of testing a patient to determine whether the patient has mutation B-positive prostate cancer.

Claims 4, 5 and 6 all contain an explicit testing step to determine whether a patient has mutation B, thereby creating a presumption that this testing step cannot be read into the respective independent claims (claims 1, 2 and 3) from which they depend.

The Supreme Court and the Federal Circuit decisions in the Limelight cases pose challenges for the enforcement of method of treatment claims that may require multiple actors to perform all of the recited steps. With artful claim drafting and the help of claim differentiation, however, one can obtain claims that can be construed as requiring only a single actor and potentially avoid this issue in litigation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.